Streetbeat News

ERNA

Eterna Therapeutics Inc.

https://www.brooklynitx.com

Industry

Biotechnology

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Open

0.68

Mkt cap

36M

Volume

189K

High

0.72

P/E Ratio

-0.16

52-wk high

2.63

Low

0.65

Div yield

N/A

52-wk low

0.65

Eterna Therapeutics Inc. has regained compliance with Nasdaq's listing requirements, ensuring its continued trading on the Nasdaq Stock Market.

Portfolio Pulse from

November 14, 2024 | 1:45 pm

Eterna Therapeutics has completed a strategic financial restructuring, reducing liabilities by discontinuing a lease, saving $72M, and cutting $700,000 in monthly cash outflow. The company also secured $5M in new financing through a PIPE investment.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 12:41 pm

Eterna Therapeutics and Factor Bioscience have entered into an exclusive license and collaboration agreement to advance the development of cell therapies for oncology, autoimmune, and rare diseases using iPSC-based technology.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 12:11 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant movements. Eterna Therapeutics, ModivCare, Cardio Diagnostics, Autolus Therapeutics, Beyond Air, and Meihua Intl Medical Techs saw notable gains. Conversely, Humana, Carmell, Tivic Health Systems, Kairos Pharma, IGM Biosciences, and Silexion Therapeutics experienced declines.

Portfolio Pulse from Benzinga Insights

October 02, 2024 | 12:05 pm

Several health care stocks experienced significant price movements during Thursday's intraday session. Notable gainers included Pasithea Therapeutics, Telesis Bio, and Adaptive Biotechnologies, while Inventiva and Theriva Biologics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

September 26, 2024 | 4:31 pm

The article highlights the intraday movements of several healthcare stocks on Wednesday. Notable gainers include Tenon Medical, Bone Biologics, and CERo Therapeutics, while Sharps Technology, Senti Biosciences, and Windtree Therapeutics were among the losers.

Portfolio Pulse from Benzinga Insights

September 25, 2024 | 2:42 pm

The article highlights significant intraday movements in health care stocks on Monday. Structure Therapeutics (GPCR) saw a 71% increase, while Concord Medical Services (CCM) rose by 55.96%. On the downside, CNS Pharma (CNSP) and Galera Therapeutics (GRTX) experienced declines of 32.2% and 31.67%, respectively.

Portfolio Pulse from Benzinga Insights

June 03, 2024 | 4:31 pm

Eterna Therapeutics Inc. announced the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity, aimed at improving the treatment of inflammatory diseases. This advancement, presented at the ASGCT Annual Meeting, promises to address batch-to-batch inconsistencies, promote in vivo persistence, and enhance cell effector function.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 12:07 pm

Eterna Therapeutics Inc received a notice from Nasdaq on March 19, indicating non-compliance with Nasdaq Listing Rule 5550(B)(1), according to an SEC filing.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 8:37 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Revance Therapeutics, Eterna Therapeutics, Connect Biopharma Hldgs, Celularity, Trxade Health, and Windtree Therapeutics were among the gainers, with increases ranging from 12.19% to 16.5%. On the downside, GRI Bio, Sharps Technology, Biofrontera, Kiora Pharmaceuticals, Cadrenal Therapeutics, and Corbus Pharmaceuticals experienced declines between 9.04% and 31.8%.

Portfolio Pulse from Benzinga Insights

February 02, 2024 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.